Lotus Neuro raises $15M from Insightec and strategic investors for FUS psychiatric neuromodulation spin-out
Summary
Lotus Neuro — spun out of Insightec to pursue focused ultrasound psychiatric applications — raised $15M in initial financing from Insightec and strategic investors to fund its depression and OCD FUS neuromodulation programs. The spin-out structure allows Lotus to pursue faster regulatory pathways and attract venture capital separately from Insightec's ablative FUS business, while retaining access to Insightec's foundational FUS technology platform.
Why it matters
Spin-outs from established MedTech companies have a strong track record in neuromodulation — they inherit technology validation, regulatory experience, and IP from the parent while gaining the operational speed and investor access of a startup. Lotus Neuro's psychiatric FUS programs could reach proof-of-concept data faster than an internal Insightec program would.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial